Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Brain and Nervous System | Pediatrics
Phase Expanded Access
What is the purpose of this trial?
The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.
- Trial withOncoceutics, Inc.
- Start Date07/10/2019
- End Date02/27/2020
- Last Updated10/30/2019
- Study HIC#2000024991